The pathogenesis and the treatment of influenza are investigated from the TCM point of view as guided by the collateral disease theory. A kind of treatment strategy with "Active Intervention" is proposed. Such famous recipes as the hemp apricot decoction recorded in the Treatise on Febrile Diseases of Han Dynasty, the use of rheum officinale for the treatment of epidemic diseases proposed in the Treatise on Pestilence of Ming Dynasty and the Lonicera and Forsythia Powder recorded in the Treatise on Differentiation and Treatment of Epidemic Febrile Diseases of Qing Dynasty are combined together into one recipe and it is proved to be with excellent therapeutic effects on the early symptoms of cold and influenza. It has a broad spectrum of therapeutic effects against viruses and bacteria and has such functions as anti-inflammation, fever relieving, resolving phlegm and relieving coughing. "Lianhua Qingwen is the best choice for anti-inflammation, fever relieving and anti-virus for such symptoms as headache, fever and aversion to cold and for the treatment of such diseases as cold, influenza and avian influenza". This product plays a very important role in such public health emergencies as the epidemic outbreaks of influenza, avian influenza and novel coronavirus pneumonia. It is a kind of product of reserve of the relevant national authorities.

• 
  

  2020, recognized as a recommended product in the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative)

  
  

• 2019, recognized as a recommended product in the Standard Therapy for Influenza (2019)

• 2018, recognized as a recommended product in the Standard Therapy for Influenza (2018, Revised)

• 2018, recognized as a recommended product in the Standard Therapy for Influenza (2018)

• 2017, recognized as a recommended product in Guideline for Clinical Application of TCM Patent Products · Treatment of Pediatric Diseases

• 2017, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

• 2016, the Phase II Clinical Trial for Lianhua Qingwen approved by US FDA started in Virginia in the US in September

• 2015, recognized as a recommended product in the Expert Consensus Document on Treatment of Cold in Special Populations

• 2015, recognized as a recommended product in the Standard Therapy for Middle East Respiratory Syndrome

• 2014, recognized as a recommended product in the Standard TCM Therapy for Ebola Virus Infections

• 2014, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

• 2013, recognized as a recommended product in the Expert Consensus Document on Medical Rescuing of Human Beings Infected by H7N9 Avian Influenza

• 2013, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

• 2012, recognized as a recommended product in the Standard TCM Therapy for Influenza B Virus Infections

• 2011, recognized as a recommended product in the Guideline on Diagnosis and Treatment of Influenza

• 2010, recognized as a recommended product in the Standard Therapy for Rheumatic Fever (Non-severe Community Acquired Pneumonia)

• 2009, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Influenza A H1N1

• 2008, recognized as a recommended product in the Instructions on Use of TCM Therapies for Prevention and Treatment of Diseases after an Earthquake

• 2008, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza (2008)

• 2005, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza

Specification:

[Drug Name] Generic name: Lianhua Qingwen Capsules

[Description] Capsules, containing tan to brown granule and powder; odour, slightly aromatic; taste, slightly bitter.

[Functions and Indications] Clear heat and detoxify, remove lung hotness. Used in treatment of epidemic influenza and lung heat, symptom as fever or high fever, aversion to cold, muscular soreness, rhinostegnosis and nasal discharge, cough, headache, dry and sore throat, flushing tongue, or greasy fur of tongue.

[Strength] [Strength]

[Administration and Dosage] For oral administration, 4 capsules once, 3 times daily.

[Adverse Reactions] Post-marketing monitoring data show that this product may cause gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, diarrhea, bloating, as well as rash, itchy ulcers, dry mouth, dizziness.

[Contraindications] Those who are allergic to this product and its ingredients should not take it.

[Precautions]

1. Avoid cigarettes, alcohol and keep from eating spicy, raw, cold or greasy food.
2. Avoid receiving nourishing Chinese medicine during the period in this product.
3. This product should not be used in treatment of wind-cold.
4. Patients with hypertension or heart disease should use with caution, patients with chronic disease such as diabetes, liver disease, kidney disease should take medicine under doctors’ direction.
5. Children, pregnant women, nursing mother, senile and infirm patients or those with week spleen should take medicine under doctors’ direction.
6. Patients with body temperature higher than 38.5 ℃ should see the doctor.
7. This product should be administered strictly in accordance with dosage and administration, and is not for long-term use.
8. Go and see the doctor if the symptom is not alleviated 3 days after administration.
9. Contraindicated for the patients allergic to this product, be cautions about patients with allergic constitution.
10. Don’t take this medicine if the description has changed.
11. Children should be administered under adults’ supervision.
12. Put this medicine beyond the children’s reach.
13. Consult with doctors or pharmacists before administration if other medicines are received during this time.
14. Athletes should use with caution.
15. Please protect from moisture after opening the moisture proof bag.

[Drug Interactions] Interaction may appear if administered accompanied with other medicine, consult with doctors or pharmacists for details.

[Storage] Preserve in tightly closed containers, stored in a cool and dry place (≤20℃).

[Package] Aluminium-plastic package, 24 capsules/box

[Shelf-life] 30 months

[Executive Standard] Chinese Pharmacopoeia 2010, the 2nd supplemental volume

[Approval No.] GYZZ Z20040063

[Revision Date] December 1st, 2013

[Manufacturer] Company name: Shijiazhuang Yiling Pharmaceutical Co., Ltd. Manufacture address: No.238 Tianshan street, New and high development area, Shijiazhuang, Hebei, China. Post code: 050035 Tel: 0086-311-85901643 Fax: 0086-311-85906730 Website: http://www.yiling.cn Any questions or problems, please do not hesitate to contact manufacturer.

SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.